Insights
How AI Is Transforming Mass Tort Case Review and Eligibility Screening for Plaintiffs’ Firms
Mass tort firms are navigating two competing realities: (1) claimant volume can surge overnight, and (2) eligibility often hinges on detailed exposure, product usage, medical timelines, and documentation that don’t fit neatly into a single “yes/no” form. That mismatch...
Depo-Provera Is Becoming a Serious Mass Tort Opportunity for Plaintiff Firms
For mass tort firms looking for the next emerging docket with real upside, Depo-Provera has moved beyond the watch-list stage. This is no longer just a theory drawing plaintiff interest. The litigation now has three signs of a docket worth serious attention: MDL...
AFFF Firefighting Foam Lawsuits: PFAS Exposure Claims Expand Nationwide
Introduction Aqueous Film-Forming Foam (AFFF), once considered essential for combating fuel-based fires, is now at the center of one of the fastest-growing mass tort litigations in the United States. Thousands of lawsuits allege that exposure to toxic “forever...
6 Ways Law Firms Can Improve Contact Form Conversions
In today’s digital age, your contact form is one of the highest-intent moments on your website: a prospective client is interested enough to reach out, but not committed enough to fight through friction, confusion, or errors. Below are six strategic ways to improve...
NEC Infant Formula Litigation: The Latest Developments in 2026
Introduction Litigation involving infant formula and necrotizing enterocolitis (NEC) continues to expand in 2026, with hundreds of lawsuits filed across the U.S. Parents of premature infants allege that cow’s milk–based formulas increased the risk of this...
Key Lessons from 2025 Mass Torts and How Firms Should Pivot in 2026
A Year That Redefined the Mass Tort Playbook Introduction The mass tort landscape in 2025 marked a clear turning point for plaintiffs firms. Traditional assumptions about volume, MDL momentum, and broad sign-ups were challenged as courts tightened standards, new...